Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13015630 | 0.84 | KMT2A (0.58) | KMT2AALDH1A1HPGDLMNAGAA | |
| SCHEMBL24417711 | 0.82 | PIK3CG (0.43) | KMT2APIK3CGPIK3CAALDH1A1HPGD | |
| SCHEMBL13801888 | 0.81 | DYRK1A (0.44) | KMT2APIK3CGPIK3CAALDH1A1HPGD | |
| SCHEMBL24417763 | 0.81 | DYRK1A (0.48) | PIK3CGPIK3CAALDH1A1HPGDNPC1 | |
| SCHEMBL2753548 | 0.80 | RAB9A (0.57) | KMT2AALDH1A1LMNALCKMEN1 | |
| SCHEMBL155142 | 0.77 | RAB9A (0.57) | KMT2APIK3CGPIK3CAALDH1A1HPGD | |
| SCHEMBL1621933 | 0.77 | KMT2A (0.49) | KMT2APIK3CGPIK3CAALDH1A1PIK3CD | |
| SCHEMBL3782912 | 0.75 | KMT2A (0.46) | KMT2AALDH1A1HPGDLMNAGAA | |
| SCHEMBL1620953 | 0.75 | KMT2A (0.46) | KMT2APIK3CGPIK3CAALDH1A1PIK3CD | |
| SCHEMBL924824 | 0.74 | ALDH1A1 (0.53) | PIK3CGPIK3CAALDH1A1HPGDPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210047312-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA | ASTRAZENECA AB (SE) | 2021-02-18 | — | — | US | disclosed |
| US-10858355-B2 | Inhibitors of phosphatidylinositol 3-kinase gamma | ASTRAZENECA AB (SE) | 2020-12-08 | — | — | US | disclosed |
| US-20200299289-A1 | NOVEL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA | ASTRAZENECA AB (SE) | 2020-09-24 | — | — | US | disclosed |
| US-9868737-B2 | Pyridino[1,2-A]pyrimidone analogue used as MTOR/P13K inhibitor | CISEN PHARMACEUTICAL CO., LTD. (CN) | 2018-01-16 | — | — | US | disclosed |
| US-20170137420-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS P13K INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-05-18 | — | — | US | disclosed |
| US-20170137420-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS P13K INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-05-18 | — | — | US | disclosed |
| US-20170129888-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS MTOR/P13K INHIBITOR | SHANGHAI JIA TAN PHARMATECH CO. LTD. (CN) | 2017-05-11 | — | — | US | disclosed |
| US-8846936-B2 | Sulfonyl compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-20130184315-A1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| EP-2217565-B1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2013-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129888-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS MTOR/P13K INHIBITOR | MTOR, PIK3CA, PIK3CD | KMT2A 2270/4885PIK3CG 14/4885PIK3CA 2/4885 |
| US-20210047312-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA | PIK3CD, PIK3CG, PIK3CA | KMT2A 3246/4885PIK3CG 2/4885PIK3CA 3/4885 |
| US-20130184315-A1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | CNR2, CNR1, GPR52 | KMT2A 3333/4885PIK3CG 2043/4885PIK3CA 2090/4885 |
| US-20170137420-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS P13K INHIBITOR | PIK3CA, PIK3CD, PIP5K1B | KMT2A 1648/4885PIK3CG 12/4885PIK3CA 1/4885 |
| US-10858355-B2 | Inhibitors of phosphatidylinositol 3-kinase gamma | PIK3CD, PIK3CG, PIK3CA | KMT2A 3246/4885PIK3CG 2/4885PIK3CA 3/4885 |
| US-20200299289-A1 | NOVEL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA | PI4KA, PIK3CD, PI4KB | KMT2A 3015/4885PIK3CG 4/4885PIK3CA 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.